Baseline bloodwork CBC, CRP, ferritin, IL-6, cortisol AM, metabolic panel, thyroid function Cardiovascular assessment heart rate variability, orthostatic vitals if POTS is suspected Gut health markers stool testing, zonulin, calprotectin if GI symptoms are prominent Mitochondrial function proxies lactate, organic acids panel if PEM is a primary complaint From there, a typical protocol might be structured as: Phase 1 (Weeks 16): Immune and gut foundation Thymosin Alpha-1: 1.6 mg subcutaneous, twice weekly BPC-157: 250500 mcg daily, route determined by predominant symptom (oral for gut, injectable for systemic) Phase 2 (Weeks 412): Tissue repair and cardiovascular recovery TB-500: 2.02.5 mg subcutaneous, twice weekly Continue BPC-157 as indicated Phase 3 (Weeks 816): Maintenance and metabolic support Taper or pulse doses based on clinical response Add mitochondrial support if fatigue persists (see: Mitochondrial Peptides and Insulin Resistance) These are illustrative dosing ranges based on clinical research and published protocols
Challenges and Responses to Expiration Date Validation Peptide degradation: The cream is prone to degradation under high temperature and high humidity conditions
while normal dietary intake is considered safe, the effects of high-dose parenteral administration are less well studied
Preservatives help maintain safety during repeated vial access sessions
Dysautonomia, particularly Postural Orthostatic Tachycardia Syndrome (POTS), frequently co-occurs with Long COVID and ME/CFS
Peptides must be stored properly to increase their shelf life and ensure that they can be used in medicinal or research purposes
